Anti Leishmanial Activities of Some Anti-Depressant Drugs and Antifungal Drugs
DOI:
https://doi.org/10.53555/nnbma.v3i4.487Keywords:
Antileishmania, Antidepressant, AntifungalAbstract
Leishmanisis is wide range, worldwide, without drug, vaccine, secticide and has not sterileimmunity and efforts in this field have not been successful.Leishmaniasis is a complex vectorborne disease caused by different species of Leishmania. It affects at least 12 million people worldwide. Leishmaniasis is commonly associated with poor economic conditions and immunecompromised situations like HIV co infection. There is increasing in drug resistance tocommonly used therapeutics as well as lack of vaccine program. This leads to a perpetual searchfor a new drug for leishmaniasis. This review fundamentally deals with some antidepressantdrugs, and antifugal drugs showing the anti leishmanial activities. The antidepressant drugs are Imipramine, Sertraline, Ketanserin and Mianserin. Imipramine being a Tri Cyclic Antidepressant(TCA) drug kills Leishmania donovani elevating IL-12/IL-10 ratio. Sertraline belonging to theselective serotonin reuptake inhibitor (SSRI) drugs, removes parasite loads from spleen and liverprobably by declining cytoplasmic ATP consumption. Ketanserin is a serotonin receptor (5-HT2A/2C) antagonist that kills both amastigotes and promastigotes probably due to inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR). Mianserin belonging to the TCAgroup of drug, kills both promastigote and amastigote parasites also probably due to theinhibition of HMGR. The present review will give the summarized information about puttingsome old antidepressant drugs for the treatment of another disease like Leishmania. Manytopical antifungals have been available, two important antibiotics: amphotericin B to deal withsystemic mycosis and griseofulvin to supplement attack on dermatophtes . A number ofantifungal agents have been investigated in a rodent model for their parasiticidal activity againstvisceral leishmaniasis. These drugs have been administered intravenously both alone, and inconjunction with liposomes. All the compounds tested: griseofulvin, 5-fluorocytosine, andamphotericin B—together with the known antileishmanial drug pentamidine—displayedenhanced therapeutic activity when given in liposomal form. In the case of amphotericin,liposomes composed of hydrogenated lecithin, or containing cholesterol or ergosterol in themembrane, were least toxic to the mammalian host, and had the highest therapeutic capability.
References
Paiva BR, et al. Detection and identification of Leishmania species in field-captured phlebotomine sandflies based on miniexon gene PCR. Acta Trop. 2006; 99:252-259.
Croft SL and Coombs GH. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 2003; 19:502-508.
Assimina Z, et al. Leishmaniasis: An overlooked public health concern. Health Sci J. 2008; 2:196-205.
Hide M, et al. Understanding Human Leishmaniasis: The need for an integrated approach in encyclopedia of infectious diseases book of microbiology. (ed by Michel T), John Wiley and Sons Inc, 2007; 87-107.
Banuls A, et al. Leishmania and the leishmaniases: A parasite genetic updates and advances in taxonomy, epidemiology and pathogenicity in humans. Adv Parasitol. 2007; 64:1-109.
Asford RW. The leishmaniases as model zoonoses. Ann Trop Med Parasitol. 1997; 91: 693-
Leishmaniasis: Epidemiology and access to medicines.
Redhu NS, et al. Leishmaniasis-HIV co-infection: an emerging problem in India, AIDS. 2006; 20:1213-1215.
Alvar J, et al. Leishmania and human immune-deficiency virus co infection: the first 10 years. Clin Microbiol Rev. 1997; 10: 298-319
Sundar S, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis. 2000; 31:1104-1107.
Sundar S. Drug resistance in Indian visceral leishmaiasis. Trop Med Int Health. 2001; 6: 849-854.
Pandey BD, et al. Short Report: Release of Visceral Leishmaniasis after Miltefosine Treatment in Nepalese Patient. Am J Trop Med Hyg. 2009; 80: 580-582.
Srivastava P, et al. Unusual case of resistance to amphotericin B in visceral leishmaniasis in a region in India where leishmaniasis is not endemic, J Clin Microbiol. 2011; 49: 3088-3091.
Monzote L. Current treatment of Leishmaniasis: A review. The open Antimicrob Agents J. 2009; 1: 9-19.
Costa CHN, et al. Vaccine for the Leishmaniases: Proposals for a research agenda. PLoS Negl Trop Dis. 2011; 5: e943.
Essentials of medical pharmacology by K.D. Tripathi seveth edition ,jaypee publication antidepressant pg no 454.
Malenka RC, et al. Ed, Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. 2009; 4.
Guzman F. Serotonin (5-HT): receptors, agonists and antagonists. Available at: http://www.pharmacologycorner.com.
Glennon RA, et al. Serotonin Recptor Subtypes and Ligands. American College of Neurophyscopharmacology. Archived from the original on 21 April 2008. Retrieved 2008-04-11.
Upadhyay SN. Serotonin Receptors, Agonists and Antagonists. Indian J Nucl Med. 2003; 18: 1-11.
David E Golan. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 2nd edition. LWW. 2008.
Harvey R and Champe P. Lippincott illustrated reviews: Pharmacology. 4th edition. LWW. 2009.
Yildiz A, et al. Mechanism of actions of antidepressants: beyond the receptors. Derlemeler/Reviews. Bull ClinPsychopharmacol. 2002; 12: 194-200.
Mukherjee S, et al. Imipramine is an orally active drug against both antimony sensitive and resistant Leishmania donovaniclinical isolates in experimental infection. PLoS Negl Trop Dis. 2012; 6: e1987.
Zilberstein D, et al. Trycyclic drugs reduce proton motive force in Leishmania donovani promastigotes. Biochem Pharmacol;1990; 39: 935-940.
Benson TJ, et al. Rationally designed selective inhibitors of trypanothione reductase. Phenothiazines and related tricyclics As lead structure. Biochem J. 1992; 286: 9-11.
Kubera M, et al. Stimulatory effect of antidepressants on the production of IL-6. Int Immunopharmacol, 2004; 4: 185-192.
Halliell WH. Cationic amphiphilic drug-induced phospholipidosis. Toxicol Pathol. 1997; 25: 53-60.
Evans AT and Croft SL. Antileishmanial actions of tricyclic neuroleptics appear to lack structural specificity. BiochemPharmacol. 1994; 48: 613-616.
Gottlieb E, et al. Mitochondrial membrane potential regulates matrix configuration and cytochrome c release duringapoptosis. Cell Death Differ. 2003; 10: 709-717.
Ly JD, et al. The mitochondrial membrane potential (deltapsi(m)) in apoptosis; an update. Apoptosis. 2003; 8: 115-128.
Chakraborty D, et al. Leishmania donovani affects antigen presentation of macrophage by disrupting lipid rafts. J Immunol.2005; 175: 3214-3224.
Mukherjee S, et al. Imipramine exploits histone deacetylase 11 to increase the IL-12/IL-10 ratio in macrophages infected with antimony-resistant Leishmania donovani and clears organ parasites in experimental infection. J Immunol. 2014; 193: 4083-4094.
Villagra A, et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. NatImmunol. 2009; 10: 92-100.
Compton SN, et al. Sertraline in children and adolescents with social anxiety disorder: an open trial. J Am Acad ChildAdolesc Psychiatry. 2001; 40:564-571.
Lass-Flori C, et al. Antifungal properties of selective serotonin reuptake inhibitors against Aspergillus species invitro. JAntimicrob Chemother. 2001; 48: 775-779.
Munoz-Bellido JL, et al. Antimicrobial activity of psychotropic drugs: selective serotonin reuptake inhibitors. Int J AntimicrobAgents. 2000; 14: 177-180.
Kumar VS, et al. The spermicidal and antitrichomonas activities of SSRI antidepressants. Bioorg Med Chem Lett. 2006;16: 2509-2512.
Tuynder M, et al. Translationally controlled tumor protein is a target of tumor reversion. Proc Natl Acad Sci USA. 2004; 101:15364-15369.
Palit P and Ali N. Oral therapy with sertraline, a selective serotonin reuptake inhibitor, shows activity against Leishmaniadonovani. J Antimicrob Chemother. 2008; 61: 1120-1124.
Person B, et al. Clinical Pharmacokinetics of ketanserine. Clin Pharmacokinet. 1991; 20: 263-279.
National Institute of Health: National Library of Medicine, Medical Subject Headings. MeSH. MeSH Descriptor Data, 2006.
Bruton, LB, Lazo JS and Parker, KL (Eds) Goodman and Gilman’s the pharmacological basis of therapeutics. 11th edition.Newyork: McGraw-Hill, 2005.
Eickhoff SB, et al. Analysis of neurotransmitter receptor distribution patterns in the cerebral cortex. Neurolmage. 2007; 34:1317-1330.
Pazos A, et al. Serotonin receptors in the Human Brain-IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience.1987; 21: 123-139.
Singh S, et al. Ketanserine, an antidepressant, exerts its antileishmanial action via inhibition of 3-hydroxy-3-methylglutarylcoenzyme A reductase (HMGR) enzyme of Leishmania donovani. Parasitol Res. 2014; 113: 2161-2168.
Ferreri M, et al. Benefits from mianserin augmentation of Fluoxetine in patients with major depressive non-responders tofluoxetine alone. Acta Psychiatr Scand. 2001; 103: 66-72.
Poyurovsky M, et al. Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients:an add-on, double-blind placebo-controlled study. Eur Neuropsychopharmacol. 2003; 13:123-128.
Shiloh R, et al. Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia. Int Clin Psychopharmacol.2002; 17: 59-64
Mizuki Y, et al. Effects of mianserin on negative symptoms in schizophrenia. Int Clin Psychopharmacol. 1990; 5: 83-95.
Control of the leishmaniasis: report of a meeting of the WHO Expert Committee on the Control of Leishmaniases (PDF). World Health Organization. March 2010. pp. 55, 88, 186. ISBN 9789241209496.
"Amphotericin B". The American Society of Health-System Pharmacists. Retrieved Jan 1,2015.
WHO Model Formulary 2008 (PDF). World Health Organization. 2009. p. 145. ISBN 9789241547659. Retrieved 8 December 2016.
Walker, S. R. (2012). Trends and Changes in Drug Research and Development. Springer Science & Business Media. p. 109. ISBN 9789400926592.
"WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Retrieved 8 December 2016.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Terms & Condition
Submission -
Author can submit the manuscript through our online submission process or email us at the designated email id in contact details.
The other mode of submission not accepted than online and email.
Before submission please read the submission guidelines.
NN Publication accepts only article submitted in pdf/doc/docx/rtf file format. Another format except given file formats will no be considered .
Author will be responsible for the error mistakes in the submission files. The minor changes can be done without any cost after publication. But for major changes NN Publication may charges you the editing charges.
Publication (Online) -
The online publication is scheduled on last date of every month, but it can be delayed by 24 to 48 hours due to editorial process if huge number of articles comes to publish in single issue.
Automatic notification email will be sent to the all users on publication of an issue, so its author’s duty to check their email inbox or SPAM folder to get this notification.
After publication of article author can not withdraw their article.
If editor’s found any issue after publication of article then the NN Publication have the authority to remove the article from online website.
No refund will be provided after online publication of article.
Publication (Print) -
The print copy publication are sent as per the author’s request after 2 weeks of online publication of that issue.
NN Publication will ship the article by India Post and provide the consignment number on dispatch of print copy.
NN Publication follows all the guidelines of delivery provided by India Post and hence not responsible for delay in delivery due to any kind of reasons.
Refund of hard copy will not be provided after dispatch or print of the journal.
NN Publication will be responsible for raise a complain if there is any issue occurs in delivery, but still will not be responsible for providing the refund.
NN Publication will be responsible to resend the print copy only and only if the print copy is lost or print copy is damaged in delivery / or there is delay more than 6 months.
According to India Post the delivery should be completed with in 1-3 weeks after dispatch of articles.
Privacy Policy-
NN Publication uses the email ids of authors and editors and readers for sending editorial or publication notification only, we do not reveal or sell the email ids to any other website or company.
